Cipher Pharmaceuticals Inc
🇨🇦XTSE.CPHCanadaNot reported
PriceCA$18.35-0.14 (-0.76%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 2
- Medium: 0
- Low: 0
Financial leverage: a sudden drop below its trailing quarter average
Leverage ratio: a sudden drop below its trailing quarter average
Free with a Finzer account.
Profile
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA17253X1050
- CUSIP
- 17253X105
Company
- Employees
- 0
- Headquarters
- Mississauga, Germany
- Website
- https://www.cipherpharma.com
Market
- Shares outstanding
- 25.4M
- Market cap
- CA$465.98M
Highlights
- Market cap
- CA$465.98M
- EPS LTM
- $0.48calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- $47.59M+114.78%up year on year
- Net income
- $12.14M-46.27%down year on year
- Gross margin
- 73.79%-9%down year on year
- Free cash flow
- $21.1M+24.04%up year on year
Latest news
News is not sourced for this exchange.
Business summary
Cipher Pharmaceuticals Inc is listed on Toronto Stock Exchange (Canada) under the ticker CPH. Its market capitalisation is CA$465.98M, from 25.4M shares outstanding, as of . Across the 141 trading sessions to the shares traded between CA$12.48 and CA$19.63, and the last close of CA$18.35 sits 82% of the way up that range. The company is headquartered in Mississauga, Germany. The same company also trades as PHE on Frankfurt Stock Exchange, and as PHE on Stuttgart Stock Exchange.
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.